Overview
- France’s Autorité de la concurrence found Doctolib dominant with an estimated 70–90% share in online medical booking and over 40% in teleconsultation.
- The decision is immediately enforceable, requiring payment to the Trésor public and an end to any remaining tying or exclusivity practices pending appeal.
- Investigators cited exclusivity clauses for practitioners and mandatory bundling that forced buyers of Doctolib’s teleconsultation to also take its booking service.
- The 2018 purchase of MonDocteur was deemed a move to lock the national market, with officials noting price rises from €109 per month at acquisition to €129 in 2019, €139 in 2021 and €149 in 2023.
- Evidence included internal documents seized in 2021 referencing plans to “killer le produit,” while Doctolib announced an appeal, disputed any dominant position, and argued its tools are technically integrated and equip about 30% of French practitioners.